MX2020009510A - Inmunoterapia combinada de beta glucano y agonista cd40. - Google Patents

Inmunoterapia combinada de beta glucano y agonista cd40.

Info

Publication number
MX2020009510A
MX2020009510A MX2020009510A MX2020009510A MX2020009510A MX 2020009510 A MX2020009510 A MX 2020009510A MX 2020009510 A MX2020009510 A MX 2020009510A MX 2020009510 A MX2020009510 A MX 2020009510A MX 2020009510 A MX2020009510 A MX 2020009510A
Authority
MX
Mexico
Prior art keywords
beta glucan
combination immunotherapy
agonist combination
agonist
combination therapy
Prior art date
Application number
MX2020009510A
Other languages
English (en)
Inventor
Nandita Bose
Gregory Beatty
Original Assignee
Hibercell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hibercell Inc filed Critical Hibercell Inc
Publication of MX2020009510A publication Critical patent/MX2020009510A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a la combinación de ß-glucano y un agonista de CD40 para la inmunoterapia contra el cáncer. La terapia de combinación muestra una actividad antitumoral sinérgica que depende de las células T. Sorprendentemente, la terapia de combinación es eficaz contra tumores poco inmunogénicos.
MX2020009510A 2018-03-13 2019-03-13 Inmunoterapia combinada de beta glucano y agonista cd40. MX2020009510A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862642210P 2018-03-13 2018-03-13
PCT/US2019/022062 WO2019178236A1 (en) 2018-03-13 2019-03-13 Beta glucan and cd40 agonist combination immunotherapy

Publications (1)

Publication Number Publication Date
MX2020009510A true MX2020009510A (es) 2021-08-05

Family

ID=67908115

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009510A MX2020009510A (es) 2018-03-13 2019-03-13 Inmunoterapia combinada de beta glucano y agonista cd40.

Country Status (12)

Country Link
US (1) US20210283168A1 (es)
EP (1) EP3765018B1 (es)
JP (1) JP7373152B2 (es)
KR (1) KR20210038839A (es)
CN (1) CN112292130A (es)
AU (1) AU2019234828B2 (es)
BR (1) BR112020018761A2 (es)
CA (1) CA3093820A1 (es)
EA (1) EA202092158A1 (es)
IL (1) IL277312A (es)
MX (1) MX2020009510A (es)
WO (1) WO2019178236A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
EP4384186A4 (en) * 2021-08-13 2025-07-02 Univ Louisville Res Found Inc INDUCTION OF TRAINED IMMUNITY FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003268486A1 (en) * 2002-09-04 2004-03-29 Biopolymer Engineering, Inc. Cancer therapy using whole glucan particles and antibodies
WO2007084661A2 (en) * 2006-01-17 2007-07-26 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2007146440A2 (en) 2006-06-15 2007-12-21 Biopolymer Engineering, Inc. Dba Biothera, Inc. Glucan preparations
JP5562837B2 (ja) 2007-05-08 2014-07-30 バイオセラ インコーポレイテッド 微粒子−可溶性グルカン調製物
EP3363462A1 (en) 2012-04-30 2018-08-22 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy
CN106170698A (zh) 2013-12-05 2016-11-30 生物治疗公司 β‑葡聚糖测定方法
WO2016007876A1 (en) 2014-07-10 2016-01-14 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
KR102443258B1 (ko) * 2014-08-12 2022-09-14 엘리게이터 바이오사이언스 에이비 항 cd40 항체에 의한 병용 치료제
HUE054075T2 (hu) * 2014-10-29 2021-08-30 Seagen Inc CD40 elleni nem fukozilált antitestek adagolása és bevitele
WO2016073763A2 (en) * 2014-11-06 2016-05-12 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
CA2971757A1 (en) * 2015-01-20 2016-07-28 Immunexcite, Inc. Compositions and methods for cancer immunotherapy
US20170158772A1 (en) * 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof

Also Published As

Publication number Publication date
JP7373152B2 (ja) 2023-11-02
BR112020018761A2 (pt) 2020-12-29
KR20210038839A (ko) 2021-04-08
AU2019234828A1 (en) 2020-10-22
AU2019234828B2 (en) 2025-02-27
EP3765018B1 (en) 2026-04-29
JP2021518433A (ja) 2021-08-02
CN112292130A (zh) 2021-01-29
CA3093820A1 (en) 2019-09-19
EA202092158A1 (ru) 2020-12-25
EP3765018A1 (en) 2021-01-20
EP3765018A4 (en) 2022-03-02
WO2019178236A1 (en) 2019-09-19
IL277312A (en) 2020-10-29
US20210283168A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
ZA202501583B (en) Compounds and methods for the targeted degradation of androgen receptor
EP4616902A3 (en) Nerve stimulation for treating migraine and other headache conditions
MX2024000253A (es) Inhibicion del smarca2 para el tratamiento del cancer.
NZ749727A (en) A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
MX2019008158A (es) Terapia de combinacion para el tratamiento del cancer.
CA3055791A1 (en) Treatment methods
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
HK1256604A1 (zh) Ezh2抑制剂和调节性t细胞功能的调制
PH12016502354A1 (en) Pharmaceutical composition
MX2017004969A (es) Metodo para tratar el cancer.
WO2013130102A3 (en) Dual ox40 agonist/il-2 cancer therapy methods
PH12018500423A1 (en) Inhibitors of ezh2
MX2022004766A (es) Terapias combinadas con venetoclax e inhibidores de tim-3.
WO2019143883A3 (en) Compositions and methods for the treatment of cancer
IL285807A (en) Immunotherapy for cancer treatment
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2022004769A (es) Inhibidores de tim-3 y sus usos.
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
MX2018004112A (es) Terapia de combinacion racional para el tratamiento de cancer.
PH12021551138A1 (en) Application of chidamide in combination with r-chop, and drug combination
PH12021550035A1 (en) Combination therapy
PH12021550376A1 (en) Combination therapy
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.